I have no idea what's going on here.
It didn't make sense to me that Acadia would trigger the row negotiations.
Unless of course they've looked at the data and think ph3 is a no brainer. AND were pumped up by the fda clearance.
Or someone else threw in a low ball offer to force the trigger.
There's some guys here that are good with company projections.
Let's forget row for now. What would neu be valued at post a successful ph3 (using the milestones and say 10% royalties)?
Roughly.
ROW Rights, page-114
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.24 |
Change
0.230(1.35%) |
Mkt cap ! $2.174B | |||
| Open | High | Low | Value | Volume |
| $17.38 | $17.54 | $17.14 | $2.386M | 137.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72 | $17.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.25 | 44 | 3 |
View Market Depth
| Last trade - 10.40am 06/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |